Identification
- Summary
Hyaluronidase is an enzyme used to improve the absorption and dispersion of parenterally administered fluids, drugs, and contrast agents.
- Brand Names
- Amphadase
- Generic Name
- Hyaluronidase
- DrugBank Accession Number
- DB14740
- Background
Hyaluronidase is an enzyme used to improve the absorption and dispersion of parenterally administered fluids, drugs, and contrast agents.8 The action of hyaluronidase was first described in 1936, and named in 1939.2 Early research into hyaluronidase identified it as a "spreading factor" which allowed for increased permeability of the connective tissue.2 Hyaluronidase has been used in surgical settings for at least the past 60 years to improve the diffusion of local anesthetics.5
Hyaluronidase was first used in prescription products in the United States on 5 May 2004.8
- Type
- Biotech
- Groups
- Approved
- Biologic Classification
- Protein Based Therapies
Other protein based therapies - Protein Chemical Formula
- Not Available
- Protein Average Weight
- Not Available
- Sequences
- Not Available
- Synonyms
- Hialuronidasa
- Hyaluronidase
- Hyaluronidase (bovine)
- Hyaluronidase bovine
- hyaluronidase-fihj
- hyaluronidase-zzxf
- Hyaluronidase, bovine
- Hyaluronidasum
- Hyaluronoglucosaminidase
Pharmacology
- Indication
Hyaluronidase is indicated for subcutaneous fluid administration for hydration, and increasing resorption of radiopaque agents in subcutaneous urography.8 Hyaluronidase is also indicated by multiple routes to increase the dispersion of other injectable drugs.8
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Therapies
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
Hyaluronidase cleaves hyaluronic acid at the glucosaminidic bond between C1 of glucosamine and C4 of glucuronic acid.4,8 Hyaluronic acid is a key component of the extracellular matrix.3 Injection of hyaluronidase with other fluids, drugs, or radiopaque agents improves the ability of these other compounds to permeate the extracellular space more easily.4,8
Target Actions Organism UHyaluronic acid modulatormetabolizerHumans and other mammals UTransforming growth factor beta-1 inhibitorHumans - Absorption
Data regarding the absorption of hyaluronidase are not readily available.8
- Volume of distribution
Data regarding the volume of distribution of hyaluronidase are not readily available.8
- Protein binding
Data regarding the protein binding of hyaluronidase are not readily available.8
- Metabolism
Data regarding the metabolism of hyaluronidase is not readily available.8 However, protein drugs are expected to be degraded by proteases and other catalytic enzymes to smaller peptides and amino acids.1
- Route of elimination
After nonspecific proteolysis, the amino acids from protein drugs are reused for protein synthesis or further broken down and eliminated by the kidneys.1,7
- Half-life
Hyaluronidase has a half life of two minutes, but a duration of action of 24-48 hours due to its high potency.6,7
- Clearance
Data regarding the clearance of hyaluronidase are not readily available.8
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Data regarding overdose of hyaluronidase is not readily available.8 In the even of an overdose, treat patients with symptomatic and supportive measures.
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your software1,2-Benzodiazepine The therapeutic efficacy of 1,2-Benzodiazepine can be decreased when used in combination with Hyaluronidase. Acetylsalicylic acid The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Acetylsalicylic acid. Amitriptyline The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Amitriptyline. Antazoline The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Antazoline. Aripiprazole The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Aripiprazole. Aripiprazole lauroxil The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Aripiprazole lauroxil. Articaine Hyaluronidase can cause an increase in the absorption of Articaine resulting in an increased serum concentration and potentially a worsening of adverse effects. Azelastine The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Azelastine. Benzatropine The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Benzatropine. Benzocaine Hyaluronidase can cause an increase in the absorption of Benzocaine resulting in an increased serum concentration and potentially a worsening of adverse effects. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- International/Other Brands
- Amphadase
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Amphadase Injection 150 [USP'U]/1mL Subcutaneous Amphastar Pharmaceuticals, Inc. 2004-10-26 Not applicable US 
Hydase Injection, solution 150 [USP'U]/1mL Infiltration; Interstitial; Intramuscular; Intraocular; Retrobulbar; Subcutaneous Akorn, Inc. 2015-11-05 2015-12-01 US Wydase Inj 150unit/ml Liquid 150 unit / mL Infiltration; Subcutaneous Wyeth Ltd. 1954-12-31 1996-09-10 Canada 
Wydase Injection Liq 150 Units/ml Liquid 150 unit / mL Infiltration; Subcutaneous Wyeth Ayerst Canada Inc. 1994-12-31 2002-06-10 Canada
Categories
- ATC Codes
- B06AA03 — Hyaluronidase
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- 8KOG53Z5EM
- CAS number
- 9001-54-1
References
- General References
- Katsila T, Siskos AP, Tamvakopoulos C: Peptide and protein drugs: the study of their metabolism and catabolism by mass spectrometry. Mass Spectrom Rev. 2012 Jan-Feb;31(1):110-33. doi: 10.1002/mas.20340. Epub 2011 Jun 22. [Article]
- Duran-Reynals F: TISSUE PERMEABILITY AND THE SPREADING FACTORS IN INFECTION : A Contribution to the Host:Parasite Problem. Bacteriol Rev. 1942 Dec;6(4):197-252. [Article]
- Walker K, Basehore BM, Goyal A, Bansal P, Zito PM: Hyaluronic Acid . [Article]
- Gilson RL, Zafar Gondal A: Hyaluronidase . [Article]
- Buhren BA, Schrumpf H, Hoff NP, Bolke E, Hilton S, Gerber PA: Hyaluronidase: from clinical applications to molecular and cellular mechanisms. Eur J Med Res. 2016 Feb 13;21:5. doi: 10.1186/s40001-016-0201-5. [Article]
- King M, Convery C, Davies E: This month's guideline: The Use of Hyaluronidase in Aesthetic Practice (v2.4). J Clin Aesthet Dermatol. 2018 Jun;11(6):E61-E68. Epub 2018 Jun 1. [Article]
- Cavallini M, Gazzola R, Metalla M, Vaienti L: The role of hyaluronidase in the treatment of complications from hyaluronic acid dermal fillers. Aesthet Surg J. 2013 Nov 1;33(8):1167-74. doi: 10.1177/1090820X13511970. Epub 2013 Nov 6. [Article]
- FDA Approved Drug Products: Vitrase Hyaluronidase Injection [Link]
- FDA News Release: FDA Approves Breast Cancer Treatment That Can Be Administered At Home By Health Care Professional [Link]
- External Links
- KEGG Drug
- D04456
- 578350
- Wikipedia
- Hyaluronidase
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Other Cardiac Output / Dehydration / Pediatrics 1 4 Completed Prevention Edema / Pain / Surgical Site Infections / Trismus 1 4 Completed Supportive Care Quality of Ocular Akinesia (Onset and Duration) 1 4 Completed Treatment Arrhythmia 1 4 Unknown Status Prevention Strabismus 1 4 Withdrawn Supportive Care Injection site bruising 1 3 Active Not Recruiting Treatment Stage I Breast Cancer 1 3 Completed Prevention Cardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Myocardial Infarction / Myocardial Ischemia 1 3 Completed Treatment Adhesive Capsulitis of Shoulder 1 3 Completed Treatment Diabetic Retinopathy (DR) / Vitreous Hemorrhage 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection Subcutaneous 150 [USP'U]/1mL Injection, powder, for solution Intravenous 1500 iu/ampoule Injection, solution Infiltration; Interstitial; Intramuscular; Intraocular; Retrobulbar; Subcutaneous 150 [USP'U]/1mL Injection, powder, for solution Parenteral Powder Conjunctival; Topical 150 U Injection, powder, lyophilized, for solution Intramuscular; Intravenous 150 IU Liquid Infiltration; Subcutaneous 150 unit / mL Injection, powder, for solution Parenteral 150 IU/1vial Injection, powder, for solution Parenteral 1500 IU/1vial - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
Targets
References
- FDA Approved Drug Products: Amphadase (hyaluronidase) injection [Link]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Type iii transforming growth factor beta receptor binding
- Specific Function
- Multifunctional protein that controls proliferation, differentiation and other functions in many cell types. Many cells synthesize TGFB1 and have specific receptors for it. It positively and negati...
- Gene Name
- TGFB1
- Uniprot ID
- P01137
- Uniprot Name
- Transforming growth factor beta-1
- Molecular Weight
- 44340.685 Da
References
- Chang NS: Hyaluronidase activation of c-Jun N-terminal kinase is necessary for protection of L929 fibrosarcoma cells from staurosporine-mediated cell death. Biochem Biophys Res Commun. 2001 May 4;283(2):278-86. [Article]
- Locci P, Marinucci L, Lilli C, Martinese D, Becchetti E: Transforming growth factor beta 1-hyaluronic acid interaction. Cell Tissue Res. 1995 Aug;281(2):317-24. [Article]
- Chang NS: Hyaluronidase enhancement of TNF-mediated cell death is reversed by TGF-beta 1. Am J Physiol. 1997 Dec;273(6 Pt 1):C1987-94. [Article]
- Chang NS: Transforming growth factor-beta protection of cancer cells against tumor necrosis factor cytotoxicity is counteracted by hyaluronidase (review). Int J Mol Med. 1998 Dec;2(6):653-9. [Article]
Drug created at February 27, 2019 23:11 / Updated at February 21, 2021 18:54